Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5850004

Title:Transgenic mouse deficient in inducible nitric oxide synthase
Inventors:MacMicking, John; New York, NY, USA
Nathan, Carl; Larchmont, NY, USA
Mudgett, John S.; Scotch Plains, NJ, USA
Summary:This invention introduces a novel transgenic nonhuman mammal, the somatic and germ cells of which are comprised of a homozygous disrupted inducible nitric oxide synthase gene. Described herein is an inducible nitric oxide synthase (iNOS)-deficient transgenic mouse, including novel replacement vectors designed for the disruption of the iNOS gene, embryonic stem cells which are singly allelic relative to the deficient iNOS locus, a host cell line or cell clone carrying a congenitally altered iNOS gene, and methods of producing such a transgenic mouse. Claims of the invention include the demonstration of an increased susceptibility to bacterial or viral infection in the mouse, and a decrease in susceptibility to sepsis as compared to a wild type mouse. Therapeutic applications include the use of such iNOS-deficient transgenic mice in the evaluation of their susceptibility to infectious or tumorigenic challenge, autoimmunity, septic shock, inflammatory and allergic diseases, for models in the treatment of such conditions in humans.
Abstract:The present invention provides an inducible nitric oxide synthase (iNOS)-deficient transgenic mouse, novel replacement vectors designed for the disruption of the iNOS gene, embryonic stem (ES) cells which are singly allelic relative to the deficient iNOS locus, a host cell line or cell clone carrying a congenitally altered iNOS gene, and a method of producing such a transgenic mouse. The iNOS-deficient transgenic mice can be used to evaluate and/or test their susceptibility to infectious or tumorigenic challenge, autoimmunity, septic shock and inflammatory and allergic diseases.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5850004
Application Number:US1997000808191
Date Filed:28/02/1997
Date Published:15/12/1998
Assignee:Cornell Research Foundation, Inc., Ithaca, NY, USA Merck and Co., Inc., Rahway, NJ, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/14/2020